Palisade Bio (PALI) Stock Forecast & Price Target

Palisade Bio is viewed favorably because PALI-2108 has already shown early mechanistic and clinical signals in small cohorts, including a 47.5% mean SES-CD reduction, a 58.8% drop in fecal calprotectin, and 5/5 clinical responses in UC after short treatment periods. The data also support a strong pharmacology profile, with ~7-fold intestinal enrichment, plasma exposure above the estimated PDE4 IC90, and only mild adverse events with no serious adverse events or discontinuations, which is important for a chronic IBD therapy. With ASCENTRA-UC in ~204 patients and ASCENTRA-CD in ~60 patients designed to validate sustained efficacy through Week 12 and beyond, the company has multiple near-term catalysts that could expand its addressable market and support later-stage advancement.

Palisade Bio is a highly speculative clinical-stage biopharma name whose valuation depends on distant 2030 launches for PALI-2108 in UC and CD, with only 40% and 30% probabilities of launch, respectively. The model’s ~$1.8B enterprise value is therefore heavily assumption-driven, while the estimated end-3Q27 cash of about $101M against ~260M fully diluted shares highlights that financing needs may persist and dilute holders. Execution risk remains substantial because efficacy, tolerability, drug activation, and enrollment delays could all undermine the program, especially amid competition from oral and biologic IBD therapies.